Tom’s of Maine Toothpaste Sued Over Bacteria — $2.9M Settlement Explained

Tom’s of Maine and its parent company Colgate-Palmolive agreed to a $2.9 million class action settlement to resolve six federal lawsuits alleging the company used bacteria-contaminated water to manufacture toothpaste, allowed mold-like substances to persist near production equipment, and continued selling the products without disclosing any of it to consumers. The lawsuits followed a damning November 2024 FDA warning letter that documented conditions at the Sanford, Maine manufacturing facility going back to 2021.

The consolidated cases, led by Rabinowitz et al. v. Colgate-Palmolive Co. et al., sit before Judge James M. Wicks in the U.S. District Court for the Eastern District of New York. The settlement received preliminary approval on March 6, 2026. The claim deadline is July 6, 2026. A final approval hearing is scheduled for September 10, 2026.

Tom’s of Maine Toothpaste Lawsuit Timeline and Updates

June 2021 — October 2022: Bacteria Detected in Manufacturing Water

The problems at Tom’s of Maine’s Sanford, Maine facility did not start in 2024. The FDA’s November 2024 warning letter documented that bacteria were first recovered in water samples used in the facility between June 2021 and October 2022. The bacteria included Pseudomonas aeruginosa, a pathogen the CDC classifies as capable of causing serious blood and lung infections, particularly in immunocompromised individuals.

That contaminated water was used to manufacture Tom’s Simply White Clean Mint Paste and to conduct the final rinse of production equipment. Batches manufactured after bacterial detections were nonetheless released based solely on microbial testing of the finished products. The underlying water supply problem was not resolved before production continued.

May 2024: FDA Inspection Uncovers “Significant Violations”

FDA investigators visited the Sanford facility between May 7 and May 22, 2024. What they found went beyond the earlier bacterial water issues. The inspection documented a “black mold-like substance” at the base of a hose reel and behind a water storage tank, positioned within a foot of equipment used for toothpaste production. Investigators also observed powder residues near a batch of Tom’s Silly Strawberry Anticavity toothpaste.

The agency determined that Tom’s of Maine’s methods, facilities, and controls for manufacturing, processing, packing, and holding product did not conform to the FDA’s Current Good Manufacturing Processes (CGMP). The violation is serious. CGMP regulations are the baseline the FDA requires every manufacturer of over-the-counter drug products to meet. Toothpastes with fluoride are regulated as OTC drugs. Tom’s had marketed its products as natural, effective, and safe. The facility where those products were made had been operating with contaminated water for years.

November 5, 2024: FDA Issues Warning Letter to Colgate-Palmolive

The FDA issued its formal warning letter to Colgate-Palmolive on November 5, 2024, addressed to the CEO of the parent company. The letter documented the full scope of the violations: Pseudomonas aeruginosa in water used for production and equipment cleaning, Ralstonia insidiosa recovered from water points of use, and Paracoccus yeei detected in a finished batch of Wicked Cool! Anticavity Toothpaste. The letter also cited roughly 400 consumer complaints about toothpaste odor, color, and taste, including complaints about children’s products, that Tom’s of Maine had failed to adequately investigate.

Tom’s of Maine responded publicly, stating it was working with the FDA and would remedy issues raised in the inspection, including upgrades to the Sanford facility’s water system. The company did not issue a product recall. Products remained on shelves.

December 2024: First Class Action Filed

The first lawsuit, Denny v. Colgate-Palmolive Co., Case No. 24-cv-02129, was filed in the Middle District of Florida. It alleged that consumers were deceived about the safety and quality of Tom’s products and would not have purchased them had they known about the manufacturing violations. Additional cases followed in quick succession: Rabinowitz v. Colgate-Palmolive Co. in New York Supreme Court, Pitre v. Colgate-Palmolive Co. in the Northern District of California, and others.

February 2025: Lead and Arsenic Allegations Added

A separate class action filed in February 2025 alleged that Tom’s of Maine’s Silly Strawberry Anticavity toothpaste, a children’s product, contained lead and arsenic at levels far exceeding proposed safety limits. Independent testing cited in that complaint found lead levels approximately 4,800 percent higher than the proposed action level. Those findings added a second wave of legal pressure on top of the bacterial contamination claims and were ultimately folded into the consolidation that produced the $2.9 million settlement.

December 19, 2025: Consolidated Complaint Filed in Eastern District of New York

Six lawsuits were consolidated under Rabinowitz et al. v. Colgate-Palmolive Co. et al., Case No. 2:25-cv-06996, in the Eastern District of New York before Judge Wicks. The consolidated complaint covered the full scope of allegations: bacteria contamination in the manufacturing process, failure to investigate consumer complaints, FDA warning letter violations, lead and arsenic in children’s toothpaste, and deceptive marketing of the products as natural and safe throughout the entire period.

March 6, 2026: Preliminary Settlement Approval Granted

The court granted preliminary approval of the $2.9 million settlement on March 6, 2026. The same date was set as the end of the class period for purchasing eligibility. Tom’s of Maine denied all wrongdoing but agreed to settle to avoid the costs and uncertainty of further litigation. After the preliminary approval, the settlement administrator opened the claim portal at ToothpasteSettlement.com and began notifying potential class members.

What the Lawsuits Alleged

The central claim across all six cases was straightforward: Tom’s of Maine sold products it marketed as natural, effective, and safe while its Sanford facility operated with contaminated water for years. Consumers buying Tom’s specifically for its natural branding, many paying a price premium over conventional toothpaste brands, received no benefit of that bargain. The products were not what the label promised.

The FDA’s warning letter, cited at length in every complaint, documented three distinct bacterial species in the production environment. Pseudomonas aeruginosa is particularly significant because it can cause serious infections resistant to antibiotics, making treatment difficult in vulnerable populations. The FDA noted that Tom’s had released batches after bacterial detections based solely on finished-product testing rather than addressing the contaminated water source. That is the kind of decision that regulators, and plaintiffs’ attorneys, consider a systemic failure rather than an isolated incident.

The complaints also emphasized the deception angle. Tom’s built its brand identity on natural ingredients and trustworthy manufacturing. Plaintiffs argued that identity was valuable precisely because consumers believed it. The moment that belief was undermined by a federal regulator, every purchase made during the contamination period became a transaction based on false premises. Plaintiffs sought the full purchase price as damages, not just partial reimbursement.

Who Qualifies to File a Claim

The settlement class excludes Colgate-Palmolive and Tom’s of Maine employees, officers, directors, and agents, as well as the presiding judge and court staff, and any class member who submits a timely opt-out request by July 6, 2026.

How Much Will the Settlement Pay

The payout depends on whether a class member submits proof of purchase. Without proof, a household can claim the average manufacturer’s suggested retail price for one Tom’s of Maine toothpaste product. Based on Tom’s current retail pricing of approximately $5.99 per tube, that is the baseline estimate, though the exact figure will be calculated from the average MSRP across the full class period.

With proof of purchase, a class member can claim a full refund for up to three products per household. Acceptable proof includes itemized receipts, loyalty card records, and bank or credit card statements showing the purchase.

All payouts are subject to pro rata adjustment. If the total value of approved claims exceeds the net settlement fund after attorney fees and administration costs are deducted, each individual payout will be reduced proportionally. If claims fall short of the fund, remaining money will be donated to Equal Justice Works, a nonprofit. Payments will not be distributed until after the final approval hearing on September 10, 2026, and the resolution of any appeals that follow.

How to File a Claim

The fastest option is submitting a claim online at ToothpasteSettlement.com. Class members enter their name, contact information, and proof of purchase if they have it. The portal also offers a PDF claim form for those who prefer to file by mail. Mail claims must be completed, signed, and postmarked by July 6, 2026. The mailing address is: Rabinowitz et al. v. Colgate-Palmolive Co., Class Administrator, P.O. Box 2897, Portland, OR 97208-2897. For questions, the settlement administrator can be reached at (877) 315-6779 or by email at the contact listed on the settlement website.

The same July 6, 2026 deadline applies to both opt-out requests and objections. If you want to exclude yourself from the settlement to preserve the right to file an independent lawsuit, you must submit a written exclusion request postmarked by that date. Staying in the class means releasing all claims related to the allegations in this case against Tom’s of Maine, Colgate-Palmolive, and related parties.

What Tom’s of Maine Knew and Did Not Say

The timeline in the FDA warning letter is worth understanding closely. Pseudomonas aeruginosa was first detected in the facility’s water between June 2021 and October 2022. That is at minimum two years before the May 2024 inspection that triggered regulatory action. During that window, Tom’s continued manufacturing. Batches made with contaminated water were released after finished-product testing, a practice the FDA criticized directly in its letter because it addressed symptoms rather than the underlying contamination source.

Tom’s also received roughly 400 consumer complaints during the relevant period about toothpaste odor, color, and taste, including complaints about children’s products. The FDA letter specifically cited the company’s failure to adequately investigate those complaints. Consumers were reporting something was off. Tom’s was not acting on those signals. The company was simultaneously running advertising that emphasized its natural ingredients, transparent manufacturing, and safety standards.

That contrast, between what consumers were being told and what the internal records showed, is the heart of what plaintiffs called deceptive and misleading business practices. Tom’s denies wrongdoing. But it agreed to pay $2.9 million rather than litigate those facts to a jury.

The Bacteria Found in Tom’s of Maine Products

Why This Settlement Matters Beyond Tom’s of Maine

Tom’s of Maine built its entire value proposition on being different from mainstream consumer brands. Natural ingredients. Environmental responsibility. Transparent manufacturing. The company charged a premium based on that identity, and millions of consumers paid it willingly. The settlement does not prove those products caused physical harm. What it establishes, at least in the civil legal record, is that the manufacturing reality at the Sanford facility diverged from the brand promise for years.

That gap is the lesson. Premium natural branding is marketing. It is not a guarantee of superior manufacturing conditions. The FDA inspects facilities on rotating schedules. The agency does not have the resources to continuously monitor every production line in every facility. Between inspections, a company’s internal quality controls and its honesty with consumers are the only protection buyers have. When those fail, as they did here, the only backstop is litigation.

Readers navigating product contamination litigation may also want to follow the Chobani phthalates lawsuit, which raised similar questions about a brand built on natural product claims. The MyChart data lawsuit and the Progressive class action settlement illustrate how large institutional defendants handle class action exposure when the cost of settlement is lower than litigation risk.

What This Lawsuit Teaches Consumers

Natural product claims carry no regulatory weight. The FDA does not require manufacturers to prove that their products are natural before using that word in marketing. A brand can position itself as transparent and thoughtfully made while operating a facility with contaminated water and unreported bacterial growth. The two are not legally connected unless a regulator catches the gap, or a lawsuit forces the facts into the public record.

The Tom’s of Maine settlement underscores three things every consumer should know. First, product recalls are reactive, not preventive. Tom’s kept selling through the contamination period, and no recall was ever issued even after the FDA letter. The products stayed on shelves. Second, consumer complaint volume matters but is often ignored. Roughly 400 complaints about odor, color, and taste were submitted. They were not adequately investigated. Third, settlements without admissions of wrongdoing are the standard outcome in these cases. Tom’s denies liability. That denial does not change the factual record in the FDA’s own documents.

If you bought Tom’s of Maine toothpaste at any point since November 2020, the claim window is open and the deadline is July 6, 2026. File even without a receipt. The process takes minutes and costs nothing. The settlement fund is $2.9 million. Unclaimed funds go to a charity, not back to the defendants. There is no reason not to file.